Patents by Inventor Yves LeBlanc

Yves LeBlanc has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
    Patent number: 6448429
    Abstract: The invention encompasses the novel class of compounds represented by formula I, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: September 10, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Yves Leblanc, Claude Dufresne, Jacques Yves Gauthier, Robert Young
  • Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
    Publication number: 20020091104
    Abstract: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme.
    Type: Application
    Filed: March 21, 2001
    Publication date: July 11, 2002
    Inventors: Chung Sing Li, Christopher Bayly, Jacques Yves Gauthier, Yves Leblanc, Cheuk Kun Lau, Patrick Roy, Michel Therien, Zhaoyin Wang, Claude Dufresne, Rejean Fortin
  • Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
    Publication number: 20020058644
    Abstract: The invention encompasses the novel class of compounds represented by formula I, which are inhibitors of the PTP-1B enzyme.
    Type: Application
    Filed: December 21, 2000
    Publication date: May 16, 2002
    Inventors: Yves Leblanc, Claude Dufresne, Jacques Yves Gauthier, Cheuk Kun Lau, Chun Sing Li, Patrick Roy, Michel Therien, John Scheigetz, Zhaoyin Wang
  • Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
    Publication number: 20020052346
    Abstract: The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme.
    Type: Application
    Filed: December 21, 2000
    Publication date: May 2, 2002
    Inventors: Cheuk Kun Lau, Christopher Bayly, Jacques Yves Gauthier, Yves Leblanc, Chun Sing Li, Patrick Roy, Michel Therien, Zhaoyin Wang
  • Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase IB (PTP-IB)
    Publication number: 20020052344
    Abstract: The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme.
    Type: Application
    Filed: December 21, 2000
    Publication date: May 2, 2002
    Inventors: Yves Leblanc, Claude Dufresne, Scheigetz John, Cheuk Kun Lau, Chun Sing Li, Patrick Roy, Michael Boyd, Zhaoyin Wang
  • Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
    Publication number: 20020052347
    Abstract: The invention encompasses the novel class of compounds represented by formula I, which are inhibitors of the PTP-1B enzyme.
    Type: Application
    Filed: December 21, 2000
    Publication date: May 2, 2002
    Inventors: Yves Leblanc, Claude Dufresne, Jacques Yves Gauthier, Robert Young
  • Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1B (PTP-1B)
    Patent number: 6365592
    Abstract: The invention encompasses compounds represented by formula I: as well as compositions and methods of treatment. The compounds are inhibitors of the PTP-1B enzyme.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: April 2, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Yves Leblanc, Claude Dufresne, Patrick Roy, Zhaoyin Wang
  • Ligands for phosphatase binding assay
    Patent number: 6348572
    Abstract: Disclosed are new ligands for use in a binding assay for proteases and phosphatases, which contain cysteine in their binding sites or as a necessary structural component for enzymatic binding. The sulfhydryl group of cysteine is the nucleophilic group in the enzyme's mechanistic proteolytic and hydrolytic properties. The assay can be used to determine the ability of new, unknown ligands and mixtures of compounds to competitively bind with the enzyme versus a known binding agent for the enzyme, e.g., a known enzyme inhibitor. By the use of a mutant form of the natural or native wild-type enzyme, in which serine, or another amino acid, e.g., alanine, replaces cysteine, the problem of interference from extraneous oxidizing and alkylating agents in the assay procedure is overcome. The interference arises because of oxidation or alkylation of the sulfhydryl, —SH (or —S−), in the cysteine, which then adversely affects the binding ability of the enzyme.
    Type: Grant
    Filed: April 29, 1998
    Date of Patent: February 19, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Sylvie Desmarais, Robert Zamboni, Richard Friesen, Yves LeBlanc, Claude Dufresne, Robert N. Young, Patrick Roy
  • Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
    Publication number: 20010016595
    Abstract: The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor.
    Type: Application
    Filed: February 28, 2001
    Publication date: August 23, 2001
    Applicant: Merck Frosst Canada Inc./Merck Frosst Canada & Co.
    Inventors: Yves Ducharme, Jacques Yves Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien
  • Phosphonic acids derivatives as inhibitors of protein tyrosine phosphate 1B (PTP-1B)
    Patent number: 6174874
    Abstract: The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases.
    Type: Grant
    Filed: September 17, 1999
    Date of Patent: January 16, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Zhaoyin Wang, Claude Dufresne, Yves Leblanc, Chun Sing Li, Jacques Y. Gauthier, Cheuk K. Lau, Michel Therien, Patrick Roy
  • (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
    Patent number: 6169188
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: January 2, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Michel Belley, Jacques Yves Gauthier, Erich Grimm, Yves LeBlanc, Chun-Sing Li, Michel Therien, Cameron Black, Petpiboon Prasit, Cheuk-Kun Lau, Patrick Roy
  • (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors
    Patent number: 6071954
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: March 13, 1998
    Date of Patent: June 6, 2000
    Assignee: Merk Frosst Canada, Inc.
    Inventors: Yves LeBlanc, Patrick Roy, Serge Leger, Erich Grimm, Zhaoyin Wang
  • (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
    Patent number: 6020343
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: June 15, 1998
    Date of Patent: February 1, 2000
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Michel Belley, Jacques Yves Gauthier, Erich Grimm, Yves LeBlanc, Chun-Sing Li, Michel Therien, Cameron Black, Petpiboon Prasit, Cheuk-Kun Lau, Patrick Roy
  • (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
    Patent number: 5981576
    Abstract: The invention encompasses the novel compound of Formula A that is useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula A.
    Type: Grant
    Filed: June 15, 1998
    Date of Patent: November 9, 1999
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Michel Belley, Jacques Yves Gauthier, Erich Grimm, Yves LeBlanc, Chun-Sing Li, Michel Therien, Cameron Black, Petpiboon Prasit, Cheuk-Kun Lau, Patrick Roy
  • Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
    Patent number: 5840746
    Abstract: The present invention provides a method of treating a neurodegenerative disease and in particular Alzheimers disease which comprises administering to a human in need thereof a therapeutically effective amount of a non-steroid COX-II inhibitor.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: November 24, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Ducharme, Jacques Yves Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien
  • Phenyl heterocycles as cox-2 inhibitors
    Patent number: 5767291
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: October 25, 1996
    Date of Patent: June 16, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Ducharme, Jacques Yves Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien
  • Phenyl heterocycles as COX-2 inhibitors
    Patent number: 5710140
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: August 16, 1996
    Date of Patent: January 20, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Ducharme, Jacques Yves Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien
  • N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
    Patent number: 5639780
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: June 17, 1997
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Cheuk Kun Lau, Cameron Black, Daniel Guay, Jacques-Yves Gauthier, Yves LeBlanc, Patrick Roy, Yves Ducharme, Pierre Hamel
  • N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
    Patent number: 5604253
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: February 18, 1997
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Cheuk K. Lau, Cameron Black, Daniel Guay, Jacques Y. Gauthier, Yves LeBlanc, Patrick Roy, Yves Ducharme, Pierre Hamel
  • Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
    Patent number: 5552422
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: January 11, 1995
    Date of Patent: September 3, 1996
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Jacques Y. Gauthier, Cheuk K. Lau, Yves LeBlanc, Chun-Sing Li, Patrick Roy, Michel Therien, Zhaoyin Wang